Scientinst inovating

Invest in Fluicell

Fluicell is an innovation-driven life science company. Our ambition is to redefine how we treat diseases by delivering next-generation regenerative medicine and drug development solutions.

The core of Fluicell's product offering is Nexocyte, our platform for universal tissue production based on our proprietary high-resolution bioprinting technology Biopixlar. With development programs in tissue-based therapies for type 1 diabetes treatment and human tissue models for cardiac safety screening, Fluicell is leading the way to solve the future’s most important health challenges and to transform the lives of millions of patients living with severe disease.

Fluicell is listed on Nasdaq First North Growth Market with the ticker FLUI.

Most recent press releases

Biopixlar printing

10 May 2024

Interim report Q1

medicine research

17 Apr 2024

Warrants TO5


For investor-related inquiries, please contact: